Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Houlihan

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Pharmaceutical Sciences|May 1, 1975
Structure determination of the anorexic agent mazindolS Barcza, W J Houlihan
Arzneimittel-Forschung|January 1, 1984
Anti-inflammatory and other pharmacodynamic properties of five members of the 4-aryl-1-isopropyl-2(1H)-quinazolinone seriesJ W Perrine, W J Houlihan, E I Takesue
European Journal of Pharmacology|May 8, 1981
Pharmacological studies with several analogs of mazindol: correlation between effects on dopamine uptake and various in vivo responsesR E Heikkila, R G Babington, W J Houlihan
Medicinal Research Reviews|May 1, 1995
Phospholipid antitumor agentsW J Houlihan, M Lohmeyer, P Workman, et al.
Journal of Medicinal Chemistry|November 1, 1971
Synthesis and antiinflammatory activity of tert-aminomethylbenzophenonesR Coombs, W J Houlihan, J Nadelson, et al.
Journal of Medicinal Chemistry|January 1, 1985
Sleep-inducing N-alkyl-5-[m-(trifluoromethyl)phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl)cinnamamidesW J Houlihan, J H Gogerty, E A Ryan, et al.
Journal of Medicinal Chemistry|March 1, 1976
Synthesis and central nervous system depressant activity of some bicyclic amidesP Aeberli, J H Gogerty, W J Houlihan, et al.
Journal of Medicinal Chemistry|May 1, 1983
Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-olsW J Houlihan, J H Gogerty, V A Parrino, et al.
International Archives of Allergy and Applied Immunology|January 1, 1986
Inhibition of rhesus monkey airway and cutaneous responses to platelet-activating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072R Patterson, K E Harris, M L Lee, et al.
Arzneimittel-Forschung|October 1, 1995
Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinolineW J Houlihan, P G Munder, D A Handley, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Pharmaceutical Sciences|May 1, 1975
Structure determination of the anorexic agent mazindolS Barcza, W J Houlihan
Arzneimittel-Forschung|January 1, 1984
Anti-inflammatory and other pharmacodynamic properties of five members of the 4-aryl-1-isopropyl-2(1H)-quinazolinone seriesJ W Perrine, W J Houlihan, E I Takesue
European Journal of Pharmacology|May 8, 1981
Pharmacological studies with several analogs of mazindol: correlation between effects on dopamine uptake and various in vivo responsesR E Heikkila, R G Babington, W J Houlihan
Medicinal Research Reviews|May 1, 1995
Phospholipid antitumor agentsW J Houlihan, M Lohmeyer, P Workman, et al.
Journal of Medicinal Chemistry|November 1, 1971
Synthesis and antiinflammatory activity of tert-aminomethylbenzophenonesR Coombs, W J Houlihan, J Nadelson, et al.
Journal of Medicinal Chemistry|January 1, 1985
Sleep-inducing N-alkyl-5-[m-(trifluoromethyl)phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl)cinnamamidesW J Houlihan, J H Gogerty, E A Ryan, et al.
Journal of Medicinal Chemistry|March 1, 1976
Synthesis and central nervous system depressant activity of some bicyclic amidesP Aeberli, J H Gogerty, W J Houlihan, et al.
Journal of Medicinal Chemistry|May 1, 1983
Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-olsW J Houlihan, J H Gogerty, V A Parrino, et al.
International Archives of Allergy and Applied Immunology|January 1, 1986
Inhibition of rhesus monkey airway and cutaneous responses to platelet-activating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072R Patterson, K E Harris, M L Lee, et al.
Arzneimittel-Forschung|October 1, 1995
Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinolineW J Houlihan, P G Munder, D A Handley, et al.
Pageof 4